𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Changes in cotherapies after initiation of disease-modifying antirheumatic drug therapy in patients with rheumatoid arthritis

✍ Scribed by Vivian K. Kawai; Carlos G. Grijalva; Patrick G. Arbogast; Jeffrey R. Curtis; Daniel H. Solomon; Elizabeth Delzell; Lang Chen; Rita Ouellet-Hellstrom; Lisa Herrinton; Liyan Liu; Edward F. Mitchel Jr.; C. Michael Stein; Marie R. Griffin

Publisher
Wiley (John Wiley & Sons)
Year
2011
Tongue
English
Weight
392 KB
Volume
63
Category
Article
ISSN
2151-464X

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Cost-effectiveness of biologics in polya
Cost-effectiveness of biologics in polyarticular-course juvenile idiopathic arthritis patients unresponsive to disease-modifying antirheumatic drugs
✍ Wendy J. Ungar; Vania Costa; Rebecca Hancock-Howard; Brian M. Feldman; Ronald M. πŸ“‚ Article πŸ“… 2010 πŸ› Wiley (John Wiley & Sons) 🌐 English βš– 150 KB πŸ‘ 1 views

## Abstract ## Objective Juvenile idiopathic arthritis (JIA) is the most common chronic pediatric rheumatic disease and can have long‐term effects leading to disability in adulthood. Biologics are a new class of drugs increasingly used to treat JIA. The primary study objective was to determine the

Change in bone mineral density in patien
Change in bone mineral density in patients with rheumatoid arthritis during the first decade of the disease
✍ Eric-Jan J. A. Kroot; Mieke G. Nieuwenhuizen; Maarten C. De Waal Malefijt; Piet πŸ“‚ Article πŸ“… 2001 πŸ› John Wiley and Sons 🌐 English βš– 83 KB πŸ‘ 1 views

Objective. Rheumatoid arthritis (RA) has been reported to be associated with bone loss during the first years of the disease. The magnitude of this problem after the initial years has not yet been evaluated. In the present study, the change in bone mineral density (BMD) in patients with recent-onset

Inhibition of neutrophil migration soon
Inhibition of neutrophil migration soon after initiation of treatment with leflunomide or methotrexate in patients with rheumatoid arthritis: Findings in a prospective, randomized, double-blind clinical trial in fifteen patients
✍ Maarten C. Kraan; Ben M. De Koster; Jan G. R. Elferink; Wendy J. Post; Ferdinand πŸ“‚ Article πŸ“… 2000 πŸ› John Wiley and Sons 🌐 English βš– 83 KB πŸ‘ 1 views

Leflunomide is a novel immunomodulating drug that has recently been approved as a disease-modifying antirheumatic drug for the treatment of rheumatoid arthritis (RA). The aim of this study was to determine the relationship between the clinical effects of leflunomide and neutrophil migration. Method